Meilleure Health International (02327.HK) plans to acquire 100% equity of Dexin Pharmaceutical Development for HK$35.2 million.

Zhito Finance APP News, Meirui Health International (02327.HK) announced that on September 21, 2026 (after trading hours), the Company entered into an agreement with the seller, Yucheng Industrial Limited, pursuant to which the seller has agreed to sell, and the Company has agreed to acquire through the purchaser, Meirui Group Development Limited (a wholly-owned subsidiary of the Company), the sale shares (representing the entire issued share capital of the target company, Dexin Pharmaceutical Development Limited), at a total consideration of HK$35.2 million.